Last reviewed · How we verify
RSV F subunit 45 μg MF59 adjuvant
RSV F subunit 45 μg MF59 adjuvant is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | RSV F subunit 45 μg MF59 adjuvant |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site pain
- Rhinorrhoea
- Upper respiratory tract infection
- Headache
- Fatigue
- Injection site induration
- Injection site erythema
- Cough
- Diarrhoea
- Nausea
- Injection site swelling
- Oropharyngeal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSV F subunit 45 μg MF59 adjuvant CI brief — competitive landscape report
- RSV F subunit 45 μg MF59 adjuvant updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about RSV F subunit 45 μg MF59 adjuvant
What is RSV F subunit 45 μg MF59 adjuvant?
RSV F subunit 45 μg MF59 adjuvant is a Biologic drug developed by GlaxoSmithKline.
Who makes RSV F subunit 45 μg MF59 adjuvant?
RSV F subunit 45 μg MF59 adjuvant is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is RSV F subunit 45 μg MF59 adjuvant in?
RSV F subunit 45 μg MF59 adjuvant is in Phase 1.
What are the side effects of RSV F subunit 45 μg MF59 adjuvant?
Common side effects of RSV F subunit 45 μg MF59 adjuvant include Injection site pain, Rhinorrhoea, Upper respiratory tract infection, Headache, Fatigue, Injection site induration.